Merck, a science and technology company, has announced that its Life Science business sector has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Wisconsin, US.
This new €59 million ($63.6m), 70,000 sqft facility brings 50 new jobs to the area.
"There is an increasing demand for HPAPIs due to their effectiveness against cancer at lower doses and the trend towards more targeted therapeutics. Lower-doses of these therapies reduce the negative side effects for patients who are taking on this critical fight," said Dirk Lange, Head of Life Science Services, Life Science, at Merck. "Increasing capacity at our state-of-the-art CDMO facility in Verona, Wisconsin will allow us to meet the need for these key cancer treatment components."
Specialised handling
Cancer is the second leading cause of death worldwide. HPAPIs are a critical element of targeted therapies due to their extremely effective cell-killing abilities at low doses, resulting in reduced side effects for patients. They are used in novel cancer therapies, including antibody-drug conjugates (ADCs), which are changing the landscape of cancer treatments.
HPAPIs require specialised handling and manufacturing facilities that protect the safety of employees and their environment. Many potential life-saving treatments never make it to market in part due to the specialised handling requirements. Merck's Verona, Wisconsin site was the second facility in the world to be SafeBridge-certified and the company continues to meet these rigorous safety and containment requirements necessary to this day.
In fact, this expansion positions Merck as one of the largest single-digit nanogram occupational exposure limit (OEL) CDMO providers in the world. HPAPIs are measured with the most potent registering less than 10 nanograms per cubic meter. Single-digit nanogram HPAPIs require highly specialised handling, which is reflected by the OEL designation.
In addition to HPAPI production, Merck also has extensive experience developing and manufacturing ADCs. Being the first CDMO to manufacture commercially approved ADC drugs in North America, the company recently launched new technologies to advance ADC therapies. Its unique ChetoSensar technology gives new promise to ADCs by alleviating solubility challenges, and Merck's new DOLCORE platform significantly reduces development and manufacturing time required, increasing speed-to-market by up to a year, ultimately getting needed therapies to patients quicker.
With more than 30 years of CDMO experience in the development and manufacturing of HPAPIs, linkers and mAbs, Merck offers significant expertise in both clinical and commercial manufacturing. The company also has extensive CDMO experience in viral vector, lipids, LNP and mRNA manufacturing -from pre-clinical to commercial- helping to streamline steps of drug development and production with a single, highly experienced partner. Additionally, BioReliance contract testing services are integrated into the overall Services offering to further streamline the development path.